NO20055181L - Krystall av benzimidazolderivat og fremgangsmate for fremstilling av samme - Google Patents

Krystall av benzimidazolderivat og fremgangsmate for fremstilling av samme

Info

Publication number
NO20055181L
NO20055181L NO20055181A NO20055181A NO20055181L NO 20055181 L NO20055181 L NO 20055181L NO 20055181 A NO20055181 A NO 20055181A NO 20055181 A NO20055181 A NO 20055181A NO 20055181 L NO20055181 L NO 20055181L
Authority
NO
Norway
Prior art keywords
preparing
crystal
same
benzimidazole derivative
benzimidazole
Prior art date
Application number
NO20055181A
Other languages
English (en)
Norwegian (no)
Other versions
NO20055181D0 (no
Inventor
Naoki Tsuchiya
Mitsuru Teramoto
Hiroshi Saiton
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33447189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20055181(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of NO20055181D0 publication Critical patent/NO20055181D0/no
Publication of NO20055181L publication Critical patent/NO20055181L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20055181A 2003-05-14 2005-11-03 Krystall av benzimidazolderivat og fremgangsmate for fremstilling av samme NO20055181L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003135567 2003-05-14
PCT/JP2004/006887 WO2004101551A1 (ja) 2003-05-14 2004-05-14 ベンズイミダゾール誘導体の結晶及びその製造方法

Publications (2)

Publication Number Publication Date
NO20055181D0 NO20055181D0 (no) 2005-11-03
NO20055181L true NO20055181L (no) 2006-01-24

Family

ID=33447189

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055181A NO20055181L (no) 2003-05-14 2005-11-03 Krystall av benzimidazolderivat og fremgangsmate for fremstilling av samme

Country Status (25)

Country Link
US (1) US7649008B2 (pt)
EP (1) EP1626048A4 (pt)
JP (1) JPWO2004101551A1 (pt)
KR (1) KR20060011997A (pt)
CN (1) CN1788007A (pt)
AR (1) AR044340A1 (pt)
AU (1) AU2004238708A1 (pt)
BR (1) BRPI0410266A (pt)
CA (1) CA2523978A1 (pt)
CL (1) CL2004001034A1 (pt)
CO (1) CO5660259A2 (pt)
EC (1) ECSP056162A (pt)
IS (1) IS8177A (pt)
MA (1) MA27805A1 (pt)
MX (1) MXPA05011851A (pt)
NO (1) NO20055181L (pt)
NZ (1) NZ542978A (pt)
PE (1) PE20050203A1 (pt)
RU (1) RU2332417C2 (pt)
SA (1) SA04250117B1 (pt)
TN (1) TNSN05288A1 (pt)
TW (1) TW200505911A (pt)
UA (1) UA81493C2 (pt)
WO (1) WO2004101551A1 (pt)
ZA (1) ZA200508640B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2004001034A1 (es) 2003-05-14 2005-03-28 Teijin Pharma Ltd Formas cristalinas de acido 4-(1-((,etilbenzotiofen-3-il)me til)benzimidazol-2-iltio)butanoico; procedimiento de preparacion de las formas cristalinas; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias, alergicas, r
AU2004266536A1 (en) * 2003-08-22 2005-03-03 Teijin Pharma Limited Drug containing chymase inhibitor as the active ingredient
WO2006052026A1 (ja) * 2004-11-12 2006-05-18 Teijin Pharma Limited ベンズイミダゾール誘導体の酸性塩及びその結晶
JP2016150917A (ja) * 2015-02-17 2016-08-22 株式会社トクヤマ バルサルタンの結晶の製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE72244T1 (de) 1986-03-21 1992-02-15 Heumann Pharma Gmbh & Co Kristalline, wasserfreie sigma -form von 2-(4-(2furoyl-(2-piperazin)-1-yl>-4-amino-6,7- dimethoxychinazolinhydrochlorid und verfahren zu ihrer herstellung.
US5015646A (en) 1987-08-28 1991-05-14 Bristol-Myers Squibb Co. Pharmaceutically useful polymorphic modification of buspirone
ES2138206T3 (es) 1994-05-31 2000-01-01 Teijin Ltd Derivados de naftaleno.
ES2150353B1 (es) 1998-04-15 2001-07-01 Esteve Labor Dr Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos.
US20040010004A1 (en) * 2000-01-17 2004-01-15 Naoki Tsuchiya Benzimidazole derivatives
JP3923255B2 (ja) 1998-07-15 2007-05-30 帝人株式会社 チオベンズイミダゾール誘導体
DE60130865T2 (de) 2000-01-17 2008-07-17 Teijin Pharma Ltd. Benzimidazol-derivate als menschliche chymase - inhibitoren
EP1362854B1 (en) 2001-02-22 2007-10-31 Teijin Pharma Limited Benzo[b[thiophene derivatives and process for producing the same
US6774245B2 (en) 2001-05-07 2004-08-10 Teijin Limited 3-Hydroxymethylbenzo[b]thiophene derivatives and process for their preparation
NZ528291A (en) 2001-08-24 2007-03-30 Teijin Ltd Drugs containing chymase inhibitor and ace inhibitor as the active ingredients
CL2004001034A1 (es) 2003-05-14 2005-03-28 Teijin Pharma Ltd Formas cristalinas de acido 4-(1-((,etilbenzotiofen-3-il)me til)benzimidazol-2-iltio)butanoico; procedimiento de preparacion de las formas cristalinas; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias, alergicas, r

Also Published As

Publication number Publication date
RU2005138868A (ru) 2006-07-10
US20060293375A1 (en) 2006-12-28
ECSP056162A (es) 2006-04-19
CO5660259A2 (es) 2006-07-31
WO2004101551A1 (ja) 2004-11-25
RU2332417C2 (ru) 2008-08-27
BRPI0410266A (pt) 2006-05-16
MA27805A1 (fr) 2006-03-01
MXPA05011851A (es) 2006-02-17
US7649008B2 (en) 2010-01-19
JPWO2004101551A1 (ja) 2006-07-13
NZ542978A (en) 2009-04-30
PE20050203A1 (es) 2005-03-26
NO20055181D0 (no) 2005-11-03
UA81493C2 (en) 2008-01-10
IS8177A (is) 2005-12-13
AR044340A1 (es) 2005-09-07
ZA200508640B (en) 2007-02-28
CA2523978A1 (en) 2004-11-25
EP1626048A1 (en) 2006-02-15
AU2004238708A1 (en) 2004-11-25
TNSN05288A1 (en) 2007-07-10
EP1626048A4 (en) 2008-11-12
CN1788007A (zh) 2006-06-14
SA04250117B1 (ar) 2009-09-02
KR20060011997A (ko) 2006-02-06
TW200505911A (en) 2005-02-16
CL2004001034A1 (es) 2005-03-28

Similar Documents

Publication Publication Date Title
CY1111295T1 (el) Παραγωγα πυριμιδινης χρησιμα για τη θεραπεια ασθενειων που προκαλουνται απο crth2
NO20081101L (no) Regioselektiv metode for fremstilling av benzimidazol-tiofener
NO20070368L (no) Virale polymeraseinhibitorer
IS7550A (is) Aðferð til framleiðslu á kvínólín-afleiðum
NO20082834L (no) 2-(fenyl eller heterosyklisk)-1H-fenantro[9,10-D]imidazoler som MPGES-1-inhibitorer
ME01530B (me) Polimorfni oblici 3- (4-amino-1- okso-1, 3-dihidro- izoindol -2-il)-piperidin-2,6- diona
NO20053546D0 (no) Triazolderivater som inhibitorer av 11-beta-hydroksysteroiddehydrogenase-1.
NO20051260L (no) Arylsubstituerte diazabicykloalkaner som nikotinacetylcholinagonister
UA101036C2 (en) Substituted 1-(diazinyl) pyrazole-4-yl-acetic acids
NO20055181L (no) Krystall av benzimidazolderivat og fremgangsmate for fremstilling av samme
NO20050087L (no) N-benzoylureido-kanelsyrederivater, fremgangsmate for fremstilling og anvendelse av disse
ATE381559T1 (de) Adamantan- und azabicyclooctan- und - nonanderivate, verfahren zu deren herstellung und deren verwendung als dpp-iv-inhibitoren
NO20041156L (no) Anordning og fremgangsmate for a sammenkople forsider av deler
ATE347550T1 (de) Polymorph von 4-(2-(4-(1-(2-ethoxyethyl)-1h- benzimidazol-2-yl)-1-piperidinyl)ethyl)-alpha, alpha-dimethylbenzolessigsäure
DK1560819T3 (da) Krystallinske cannabinoidderivater og fremgangsmåde til cannabinoidrensning
NO20071012L (no) Fremgangsmate for fremstilling av D-erytro-2,2-difluor-2-deoksy-1-oksoribosederivat
ATE426718T1 (de) Sterilisationsanlage und verfahren zum vergríssern der kapazitat fur eine sterilisationsanlage
NO20083068L (no) Optisk aktive karbamater, fremgangsmate for deres fremstilling og anvendelse derav som farmasoytiske mellomprodukter
DE60318142D1 (de) Verstärker für breitbandige optische Ramanverstärkung
NO20081621L (no) Tetrahydrokinoliner, syntese og intermediater
DK1403265T3 (da) Industriel fremgangsmåde til fremstilling af 5-bis(carboxymethyl)amino-3-carboxymethyl-4-cyano-2-thiophencarboxylsyretetraestre og anvendelse heraf til syntese af divalente ranelsyresalte og hyddrater heraf
MXPA05010875A (es) Derivados de piperazina como inhibidores de renina.
NO20071634L (no) Effektiv syntese av 4,5-dihydro-pyrazolo(3,4-C)pyrid-2-oner
NO20071325L (no) Fremgangsmate for fremstilling av hemicellulose fra lignocellulosemateriale
NO20073276L (no) Metode for fremstilling av aminoetoksybenzylalkoholer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application